For a small bio-medical device company with foundational IP encompassing non-invasive methods of treating various ophthalmologic conditions, we battled for two years with the USPTO over the scope of claims, finally succeeding in submitting key data and arguments which garnered allowance without jeopardizing claim scope. The issuance of two additional US patents covering related methods quickly followed, and our world-wide strategy produced similar results.
A global biotechnology company asked us to conduct IP due diligence on a technology it wanted to acquire. In less than two weeks, we evaluated over 200 US patents and pending US and international applications, mapped out a timeline of the IP landscape in relevant antisense technology over the past 25 years, and provided our opinion regarding freedom to operate with the technology to be acquired.
A major research university asked us to evaluate one of its US patents in preparation for litigation to enforce patent rights. The claims of the patent were being allegedly infringed by the sale of a recently approved drug with over $2 billion in annual sales. We reviewed each claim, term by term, to provide systematic support for claim construction and provided our client with an opinion on enforceability against the infringing product.
A new client thought it had a dominant IP position based on patents filed years earlier. We were asked to do diligence and a freedom-to-operate opinion respecting a lead product. We uncovered a series of prior art documents that would have undermined the client’s position in the eyes of an investor. The client bought the competitor’s IP, took a new position in-line with the discovered prior art, yielding a strong valuation and investment.
We conducted multiple patent due diligence projects for a clinical-stage, biopharmaceutical company related to both small-molecule and antibody therapeutics, including analyzing strengths of granted and pending patent claims and possible hurdles to overcome, focusing on large business markets such as the US and Europe.
A large hedge fund client sought our advice to help it decide whether to invest in a small pharmaceutical company whose patent portfolio might prevent a large pharmaceutical company from making and selling a blockbuster drug. We performed due diligence to determine the strengths of the patent portfolios of the pharmaceutical companies, the likelihood of success of the small pharmaceutical company in a potential interference proceeding against the large pharmaceutical company in the US, and the likelihood of success of the pharmaceutical companies in various opposition proceedings in Europe. Based on our due diligence report, our client invested heavily in the small pharmaceutical company.
After unsuccessful attempts by prior counsel, we overcame extensive and resolute rejections from a USPTO examiner to secure multiple patents covering the client’s proposed new formulation of a previously-approved drug and claims to the active pharmaceutical ingredient itself based on an unexpectedly improved purity profile.
We successfully petitioned the USPTO to revive an application unintentionally abandoned more than two years earlier as a result of misrepresentations and malfeasance of prior counsel.
A client approached us to prosecute patent applications directed to its composition used to treat nerve and pain issues, as well as systems and methods for producing the composition. Despite numerous rejections alleging that the composition was merely an ordinary combination of well-known components, and the systems and methods were simple variations of what was previously disclosed, we secured broad international patent protection covering the composition, its uses, as well as systems and methods for its production.
